{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:19:53Z","timestamp":1794673193881,"version":"4.9.1"},"reference-count":154,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T00:00:00Z","timestamp":1727568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the production of autoreactive B and T cells and cytokines, leading to chronic inflammation affecting multiple organs. SLE is associated with significant complications that substantially increase morbidity and mortality. Given its complex pathogenesis, conventional treatments for SLE often have significant side effects and limited efficacy, necessitating the exploration of novel therapeutic strategies. One promising approach is the use of chimeric antigen receptor (CAR)-T-cell therapy, which has shown remarkable success in treating refractory hematological malignancies. This review provides a comprehensive analysis of the current use of CAR-T-cell therapy in SLE.<\/jats:p>","DOI":"10.3390\/ijms251910511","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T03:12:28Z","timestamp":1727665948000},"page":"10511","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1573-5494","authenticated-orcid":false,"given":"Haneen M.","family":"Abdalhadi","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter W.","family":"Chatham","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Nevada, Las Vegas, NV 89102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3770-471X","authenticated-orcid":false,"given":"Fatima K.","family":"Alduraibi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA"},{"name":"Department of Medicine, Division of Clinical Immunology and Rheumatology, Harvard Teaching Hospital, Boston, MA 02215, USA"},{"name":"Department of Medicine, Division of Clinical Immunology and Rheumatology, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13075-022-02766-1","article-title":"Lupus nephritis correlates with B cell interferon-\u03b2, anti-Smith, and anti-DNA: A retrospective study","volume":"24","author":"Alduraibi","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/1756-185X.12490","article-title":"Biologic therapies in systemic lupus erythematosus","volume":"18","author":"Bernal","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhu, L., Zhang, H., Chen, S., and Xiao, Y. (2022). CAR-T cell therapy in hematological malignancies: Current opportunities and challenges. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.927153"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/rheumatology\/kead616","article-title":"Chimeric antigen receptor T cell therapy: A new emerging landscape in autoimmune rheumatic diseases","volume":"63","author":"Lyu","year":"2024","journal-title":"Rheumatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood-2023-180547","article-title":"CD19-targeted CAR-T cells in refractory systemic autoimmune diseases: A monocentric experience from the first fifteen patients","volume":"142","author":"Mueller","year":"2023","journal-title":"Blood"},{"key":"ref_11","first-page":"93","article-title":"OP0141\u2005long term safety and efficacy of car-t cell treatment in refractory systemic lupus erythematosus\u2014Data from the first seven patients","volume":"82","author":"Taubmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 chimeric antigen receptor T cell treatment: Unraveling the role of b cells in systemic lupus erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.4110\/in.2022.22.e37","article-title":"Engineering cell therapies for autoimmune diseases: From preclinical to clinical proof of concept","volume":"22","author":"Oh","year":"2022","journal-title":"Immune Netw."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kaminski, D.A., Wei, C., Qian, Y., Rosenberg, A.F., and Sanz, I. (2012). Advances in human B cell phenotypic profiling. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00302"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biocel.2009.10.011","article-title":"The role of B cells in lupus pathogenesis","volume":"42","author":"Nashi","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1084\/jem.180.4.1295","article-title":"The role of B cells in lpr\/lpr-induced autoimmunity","volume":"180","author":"Shlomchik","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1756286418761697","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: Differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1093\/rheumatology\/keac150","article-title":"Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab","volume":"61","author":"Arnold","year":"2022","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"Kaufmann","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/0976-500X.85930","article-title":"Belimumab: First targeted biological treatment for systemic lupus erythematosus","volume":"2","author":"Dubey","year":"2011","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","article-title":"Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: Results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): Results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0961203316654767","article-title":"Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the phase 2 clinical trial with blisibimod","volume":"26","author":"Petri","year":"2017","journal-title":"Lupus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1093\/rheumatology\/keab115","article-title":"Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus","volume":"60","author":"Wallace","year":"2021","journal-title":"Rheumatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14712598.2022.2026921","article-title":"Prospects for CAR T cell immunotherapy in autoimmune diseases: Clues from Lupus","volume":"22","author":"Radic","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1191\/0961203304lu525oa","article-title":"Autologous stem cell transplantation for systemic lupus erythematosus","volume":"13","author":"Jayne","year":"2004","journal-title":"Lupus"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.autrev.2005.03.003","article-title":"Hemopoietic stem cell transplantation in rheumatic diseases\u2014An update","volume":"4","author":"Khanna","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Jayaraman, J., Mellody, M.P., Hou, A.J., Desai, R.P., Fung, A.W., Pham, A.H.T., Chen, Y.Y., and Zhao, W. (2020). CAR-T design: Elements and their synergistic function. EBioMedicine, 58.","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity","volume":"173","author":"Chmielewski","year":"2004","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Dejenie","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: A quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3 zeta signaling receptor molecule","volume":"167","author":"Hombach","year":"2001","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4049\/jimmunol.144.5.1585","article-title":"Antigen presentation by resting B cells. Effectiveness at inducing T cell proliferation is determined by costimulatory signals, not T cell receptor occupancy","volume":"144","author":"Jenkins","year":"1990","journal-title":"J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2019-125423","article-title":"Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients","volume":"134","author":"Schubert","year":"2019","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., and Zhang, X. (2022). Strategies to enhance CAR-T persistence. Biomark. Res., 10.","DOI":"10.1186\/s40364-022-00434-9"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: Results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41571-021-00485-1","article-title":"Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells \u2018off the shelf\u2019?","volume":"18","author":"DiNofia","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: Foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/10408363.2019.1633512","article-title":"Production of CAR T-cells by GMP-grade lentiviral vectors: Latest advances and future prospects","volume":"56","author":"Poorebrahim","year":"2019","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.12773","article-title":"CAR T cells for brain tumors: Lessons learned and road ahead","volume":"290","author":"Akhavan","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/1573397119666230214103044","article-title":"Autologous CD19-targeted chimeric antigen receptor (CAR)T-cells as the future of systemic lupus erythematosus treatment","volume":"19","author":"Kambayana","year":"2023","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014A case series with follow-up","volume":"390","author":"Taubmann","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Wang, W., He, S., Zhang, W., Zhang, H., DeStefano, V.M., Wada, M., Pinz, K., Deener, G., Shah, D., and Hagag, N. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: A phase 1 open-label clinical trial. Ann. Rheum. Dis., 2024.","DOI":"10.1136\/ard-2024-225785"},{"key":"ref_78","unstructured":"Hern\u00e1ndez, J.C., Barba, P., Alberich, M.L., Fischer, O., Kovacs, B., Calzascia, T., Pearson, D., Garrotte, A.L.J., Kirsilae, T., and Siegel, R. (2023). An open-label, multi-center, phase 1\/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-T cell therapy targeting CD19 on B cells, for severe refractory systemic lupus erythematosus: Preliminary results. Arthritis Rheumatol., 75."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"ref_80","first-page":"A109","article-title":"First two US patients with lupus nephritis (LN) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy: Preliminary results from the KYSA-1 phase 1, multicenter study of KYV-101","volume":"11","author":"Podoll","year":"2024","journal-title":"Lupus Sci. Med."},{"key":"ref_81","first-page":"A113","article-title":"Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus","volume":"11","author":"Marasco","year":"2024","journal-title":"Lupus Sci. Med."},{"key":"ref_82","unstructured":"European Alliance of Associations for Rheumatology (2024, June 24). Welcome to EULAR\u2019s Abstract Archives. Available online: https:\/\/scientific.sparx-ip.net\/archiveeular\/?c=s&view=1&searchfor."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B cells in murine lupus: Efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.27515","article-title":"Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus","volume":"62","author":"Bekar","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.stem.2014.01.007","article-title":"Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis","volume":"14","author":"Zhao","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3324\/haematol.2010.030536","article-title":"Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes","volume":"96","author":"Feng","year":"2011","journal-title":"Haematologica"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood-2003-10-3438","article-title":"Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support","volume":"103","author":"Bernad","year":"2004","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0320-5","article-title":"Interleukin-6 signaling regulates hematopoietic stem cell emergence","volume":"51","author":"Tie","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1359\/jbmr.1997.12.3.412","article-title":"Nitric oxide acts in conjunction with proinflammatory cytokines to promote cell death in osteoblasts","volume":"12","author":"Damoulis","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.micpath.2016.08.038","article-title":"Mce4A protein of Mycobacterium tuberculosis induces pro inflammatory cytokine response leading to macrophage apoptosis in a TNF-\u03b1 dependent manner","volume":"100","author":"Saini","year":"2016","journal-title":"Microb. Pathog."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-cell all receiving CAR T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Zhou, J., Zhang, Y., Shan, M., Zong, X., Geng, H., Li, J., Chen, G., Yu, L., Xu, Y., and Li, C. (2022). Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.997589"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jcyt.2022.11.001","article-title":"Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy","volume":"25","author":"Wang","year":"2023","journal-title":"Cytotherapy"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Qi, K., Yan, Z., Cheng, H., Chen, W., Wang, Y., Wang, X., Cao, J., Zhang, H., Sang, W., and Zhu, F. (2021). An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: A single-centre retrospective study. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.691064"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: A critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_110","unstructured":"U.S. Department of Health and Human Services (2018, April 22). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5\u00d77.pdf."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","article-title":"Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK medical research council ALL97 randomized trial","volume":"129","author":"Mitchell","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1759720X11407540","article-title":"Tocilizumab: A novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis","volume":"3","author":"Alten","year":"2011","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000338179","article-title":"Critical imbalance of TNF-\u03b1 and soluble TNF receptor 1 in a patient with macrophage activation syndrome: Potential implications for diagnostics and treatment","volume":"128","author":"Flammiger","year":"2012","journal-title":"Acta Haematol."},{"key":"ref_115","first-page":"705","article-title":"Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: Clinical evidence to date","volume":"16","author":"Si","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","article-title":"IL-1 pathways in inflammation and human diseases","volume":"6","author":"Gabay","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_117","first-page":"2120","article-title":"Etanercept in the treatment of macrophage activation syndrome","volume":"28","author":"Prahalad","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2018-05-846428","article-title":"Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques","volume":"132","author":"Nellan","year":"2018","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE)","volume":"105","author":"Chabannon","year":"2020","journal-title":"Haematologica"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_124","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2386187","DOI":"10.1155\/2018\/2386187","article-title":"Immunotherapy with CAR-modified T cells: Toxicities and overcoming strategies","volume":"2018","author":"Sun","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2217\/imt-2017-0070","article-title":"Coccidioidomycosis, immunoglobulin deficiency: Safety challenges with CAR T cells therapy for relapsed lymphoma","volume":"9","author":"Zahid","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc \u2018spacer\u2019 domain in the extracellular moiety of chimeric antigen receptors avoids \u2018off-target\u2019 activation and unintended initiation of an innate immune response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","article-title":"Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions","volume":"14","author":"Curran","year":"2012","journal-title":"J. Gene Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"ref_137","unstructured":"Food and Drug Administration (2024, August 03). Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-development-chimeric-antigen-receptor-car-t-cell-products."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_139","unstructured":"US Food & Drug Administration (2023, November 28). FDA Investigating Serious Risk of T-Cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: Next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_141","unstructured":"Wu, L.L. (2024, June 16). FDA\u2019s Peter Marks Says Some Secondary Cancer Cases after CAR-T Therapy May Be \u2018Causal,\u2019 But Benefits Still Outweigh Risks: #JPM24. Available online: https:\/\/endpts.com\/jpm24-fdas-peter-marks-says-some-secondary-cancer-cases-after-car-t-therapy-may-be-causal-but-benefits-still-outweigh-risks\/."},{"key":"ref_142","unstructured":"US Food & Drug Administration (2024, June 14). FDA Requires Boxed Warning for T Cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"key":"ref_145","unstructured":"European Medicines Agency (2024, April 11). Pharmacovigilance Risk Assessment Committee (PRAC), Available online: https:\/\/www.ema.europa.eu\/en\/committees\/pharmacovigilance-risk-assessment-committee-prac."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Bouziana, S., and Bouzianas, D. (2024). The current landscape of secondary malignancies after CAR T-cell therapies: How could malignancies be prevented?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179518"},{"key":"ref_147","unstructured":"US Food & Drug Administration (2023, November 28). BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies: FDA Safety Communication\u2014FDA Investigating Serious Risk of T-Cell Malignancy, Available online: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/bcma-directed-or-cd19-directed-autologous-chimeric-antigen-receptor-car-t-cell-immunotherapies-fda."},{"key":"ref_148","unstructured":"Hu, L. (2022, December 02). Clinical Development of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Cancer, Available online: https:\/\/www.fda.gov\/media\/167537\/download."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2021.39.15_suppl.7555","article-title":"Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy","volume":"39","author":"Bansal","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/blood-2019-122067","article-title":"Impact of anti-CD19 CAR-T axicabtagene ciloleucel on vaccine titers of DTaP and MMR","volume":"134","author":"Rahman","year":"2019","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/S2666-6367(21)00456-5","article-title":"High rates of residual vaccine titers at 1-year post CD19 chimeric antigen receptor T cell therapy","volume":"27","author":"Shah","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_152","first-page":"e146743","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e003428","DOI":"10.1136\/jitc-2021-003428","article-title":"Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: A prospective observational study","volume":"9","author":"Walti","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10511\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:06:46Z","timestamp":1760112406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,29]]},"references-count":154,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ijms251910511"],"URL":"https:\/\/doi.org\/10.3390\/ijms251910511","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,29]]}}}